Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
19.51
Nov 19 • 2:32 PM ET Dollar change-0.30 Percentage change(-1.51%)
Index
RUT
Market Cap
1.85B
Enterprise Value
1.67B
Income
-271.03M
Sales
0.00M
Book/sh
2.16
Cash/sh
3.25
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
465
IPO
Jul 20, 2018
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
9.03
P/C
6.01
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
6.90
Current Ratio
7.11
Debt/Eq
0.62
LT Debt/Eq
0.60
Option/Short
Yes / Yes
EPS (ttm)
-2.92
EPS next Y
-1.30
EPS next Q
-0.58
EPS this Y
31.35%
EPS next Y
43.89%
EPS next 5Y
-
EPS past 3/5Y
-4.15% -14.11%
Sales past 3/5Y
- -
EPS Y/Y TTM
19.12%
Sales Y/Y TTM
-
EPS Q/Q
39.93%
Sales Q/Q
-
Insider Own
5.95%
Insider Trans
-4.94%
Inst Own
120.11%
Inst Trans
17.37%
ROA
-71.01%
ROE
-115.80%
ROIC
-82.65%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
2.12%
SMA50
28.18%
SMA200
90.17%
Trades
Shs Outstand
94.81M
Shs Float
89.16M
52W High
23.54 -17.11%
52W Low
1.50 1200.77%
Volatility
6.54% 8.52%
ATR (14)
1.29
RSI (14)
56.73
Beta
0.88
Rel Volume
0.45
Avg Volume
2.55M
Volume
890,527
Perf Week
-11.23%
Perf Month
66.48%
Perf Quarter
32.10%
Perf Half Y
273.78%
Perf YTD
100.74%
Perf Year
117.04%
Perf 3Y
87.61%
Perf 5Y
-43.03%
Perf 10Y
-
Prev Close
19.81
Price
19.51
Change %
-1.51%
Consensus
Strong Buy
Avg. Price Target
$24.57
Implied Upside
+25.9%
Analysts8incl. previous ratings
Rating Distribution5 Buy · 2 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 07, 2026Upgrade
WWedbush
Neutral → Outperform$12-38.5%
Aug 04, 2026Upgrade
LLeerink Partners
Market Perform → Outperform$17-12.9%
Jul 31, 2026Upgrade
WWedbush
Neutral → Outperform$12-38.5%
Jul 31, 2026Upgrade
CCantor Fitzgerald
Neutral → Overweight
Jun 30, 2026Upgrade
BMO logoBBMO Capital Markets
Underperform → Outperform$16-18.0%
Jun 26, 2026Upgrade
JPM logoJJP Morgan
Neutral → Overweight$17-12.9%
May 29, 2026Upgrade
JPM logoJJP Morgan
Underweight → Neutral$8-59.0%
Apr 13, 2026Downgrade
WWedbush
Outperform → Neutral$2-89.7%
Apr 13, 2026Downgrade
LLeerink Partners
Outperform → Market Perform$2-89.7%
Apr 13, 2026Downgrade
JPM logoJJP Morgan
Neutral → Underweight
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Xynos KonstantinosChief Medical OfficerNov 16 '26Sale21.6016,198349,877208,017Nov 18 07:32 PM
Schwendenman AndrewChief Accounting OfficerNov 16 '26Sale21.602,14846,39797,277Nov 18 07:31 PM
Patel SushilChief Executive OfficerNov 16 '26Sale21.6049,0261,058,962659,125Nov 18 07:31 PM
Hill Emily LuisaChief Financial OfficerNov 16 '26Sale21.6014,709317,714201,143Nov 18 07:30 PM
VELEKA PEEPLES-DYERDirectorNov 17 '26Proposed Sale20.1034,500693,544Nov 17 05:34 PM
SLATTERY JOSEPH PDirectorNov 09 '26Sale21.805,200113,3601,467Nov 10 04:30 PM
JOSEPH P SLATTERYDirectorNov 09 '26Proposed Sale21.805,200113,360Nov 09 05:35 PM
Dhingra KapilDirectorNov 02 '26Option Exercise1.7543,16975,54643,169Nov 03 08:43 PM
Dhingra KapilDirectorNov 02 '26Sale19.0021,500408,50021,669Nov 03 08:43 PM
PAOLO PUCCIDirectorNov 03 '26Proposed Sale20.43138,7002,833,988Nov 03 04:29 PM
Kapil DhingraDirectorNov 02 '26Proposed Sale17.7516,500292,875Nov 02 04:08 PM
VELEKA PEEPLES-DYERDirectorOct 30 '26Proposed Sale16.7210,000167,232Oct 30 04:34 PM
VELEKA PEEPLES-DYERDirectorOct 28 '26Proposed Sale12.9012,000154,745Oct 28 04:02 PM
Hill Emily LuisaChief Financial OfficerAug 17 '26Sale14.289,256132,176215,852Aug 19 06:42 PM
Patel SushilChief Executive OfficerAug 10 '26Sale12.9739,341510,253708,151Aug 12 05:07 PM
Hill Emily LuisaChief Financial OfficerAug 10 '26Sale12.9711,448148,481225,108Aug 12 05:06 PM
Xynos KonstantinosChief Medical OfficerAug 10 '26Sale12.9711,447148,468224,215Aug 12 05:05 PM
Schwendenman AndrewChief Accounting OfficerAug 10 '26Sale12.977,63298,98799,425Aug 12 05:04 PM
Sarchi ChristopherChief Commercial OfficerJun 01 '26Sale9.2412,000110,880180,962Jun 03 08:30 PM
Xynos KonstantinosChief Medical OfficerMay 18 '26Sale5.0814,02371,237235,662May 20 04:18 PM
Schwendenman AndrewChief Accounting OfficerMay 18 '26Sale5.087,89440,102107,057May 20 04:17 PM
Sarchi ChristopherChief Commercial OfficerMay 18 '26Sale5.088,62643,820192,962May 20 04:16 PM
Astley-Sparke PhilipDirectorMay 18 '26Sale5.0817,65789,6981,412,414May 20 04:16 PM
Patel SushilChief Executive OfficerMay 18 '26Sale5.0837,324189,606747,492May 20 04:15 PM
Hill Emily LuisaChief Financial OfficerMay 18 '26Sale5.087,81239,685236,556May 20 04:15 PM
Sarchi ChristopherChief Commercial OfficerApr 02 '26Sale8.016,50052,065151,588Apr 06 04:30 PM
Christopher SarchiOfficerApr 02 '26Proposed Sale7.7018,500142,450Apr 02 04:15 PM
Dhingra KapilDirectorDec 09 '25Option Exercise1.753,1695,5463,169Dec 11 04:30 PM
Dhingra KapilDirectorDec 09 '25Sale10.403,16932,9580Dec 11 04:30 PM
Kapil DhingraDirectorDec 09 '25Proposed Sale10.383,16432,842Dec 09 04:00 PM
Patel SushilChief Executive OfficerDec 02 '25Sale11.1310,000111,300333,576Dec 04 04:30 PM
Sushil PatelChief Strategy OfficerDec 02 '25Proposed Sale11.1310,000111,303Dec 02 04:11 PM
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
CEO & DirectorDr. Sushil Patel Ph.D.
Chief Financial OfficerMs. Emily Luisa Hill
M.D.Dr. Konstantinos Xynos M.B.A.
Executive ChairmanMr. Philip Astley-Sparke F.S.A.
Chief Operations OfficerMs. Nina Aragam